- Trials with a EudraCT protocol (48)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
48 result(s) found for: Citrulline.
Displaying page 1 of 3.
EudraCT Number: 2015-005792-25 | Sponsor Protocol Number: R04341 | Start Date*: 2017-12-22 | ||||||||||||||||||||||||||
Sponsor Name:Manchester University NHS Foundation Trust | ||||||||||||||||||||||||||||
Full Title: Feasibility study on the effects of L-citrulline on uteroplacental and cardiovascular function in hypertensive pregnant women | ||||||||||||||||||||||||||||
Medical condition: The medical condition that is to be investigated in this study is essential hypertension in pregnant women. In this study it is defined as diastolic BP of ≥90 mmHg (average of two clinic readings) ... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults | Gender: Female | |||||||||||||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-002427-28 | Sponsor Protocol Number: CIT-003-01 | Start Date*: 2018-10-24 |
Sponsor Name:Asklepion Pharmaceuticals, LLC | ||
Full Title: A Phase III Double-Blind, Randomized, Placebo Controlled, Multi-Center Clinical Study to Evaluate the Efficacy and Safety of Intravenous L-citrulline for the Prevention of Clinical Sequelae of Acut... | ||
Medical condition: Post-operative pulmonary dysfunction induced by cardiopulmonary bypass in pediatric subjects undergoing surgery for congenital heart defects. | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) AT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2013-005499-16 | Sponsor Protocol Number: 2013-624 | Start Date*: 2014-01-31 | |||||||||||||||||||||
Sponsor Name:Rigshospitalet, 2121 | |||||||||||||||||||||||
Full Title: Pilot Study with Treatment of Short Bowel Syndrome Patients with end-jejunostomi with the Glucagon-Like Peptide-1 analogue, Liraglutide (Victoza®) | |||||||||||||||||||||||
Medical condition: Short Bowel Syndrome with intestinal failure (SBS IF) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DK (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-000824-36 | Sponsor Protocol Number: HLSC-UCD-01 | Start Date*: 2021-12-09 | |||||||||||
Sponsor Name:Unicyte AG | |||||||||||||
Full Title: An open-label, controlled, multi-site, Phase I clinical trial to assess the ureagenesis capacity in newborns and infants up to the age of 12 months with neonatal and infantile onset of urea cycle d... | |||||||||||||
Medical condition: Subject has a genetically confirmed diagnosis of any of the following urea cycle disorders: ASS, CPS1, ASL, OTC Subjects without UCD can have other stable illness that not interfere with the clini... | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) AT (Prematurely Ended) IT (Prematurely Ended) BE (Completed) DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005791-35 | Sponsor Protocol Number: SHP633-302 | Start Date*: 2020-12-23 |
Sponsor Name:Shire | ||
Full Title: A 24-week Safety, Efficacy, Pharmacodynamic, and Pharmacokinetic Study of Teduglutide in Japanese Pediatric Subjects, Aged 4 Months Through 15 Years, With Short Bowel Syndrome Who Are Dependent on ... | ||
Medical condition: Treatment of short bowel syndrome dependent on parenteral support | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2004-000439-27 | Sponsor Protocol Number: CL0600-005 | Start Date*: 2007-10-29 |
Sponsor Name:NPS Allelix Corporation | ||
Full Title: A Study of the Safety and Efficacy of Teduglutide in Subjects with Parenteral Nutrition-Dependant Short Bowel Syndrome Who Completed Protocol CL0600-004 | ||
Medical condition: Short Bowel Syndrome (SBS) refers to the clinical situation whereby a significant reduction in the absorptive capacity of the intestine results from inadequate anatomical or functional length of re... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DK (Completed) | ||
Trial results: View results |
EudraCT Number: 2022-000849-32 | Sponsor Protocol Number: 1/2022 | Start Date*: 2022-05-10 |
Sponsor Name:Helsinki University Hospital | ||
Full Title: The effect of tenofovir disoproxil fumarate (TDF) versus tenofovir alafenamide (TAF) on proximal small intestine – a potential mechanism to explain opposing effects on body weight | ||
Medical condition: HIV-positive people who have good and stable treatment response for HIV-medication which includes either tenofovir disoproxil (TDF) or tenoforvir alafenamide (TAF) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FI (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2015-002252-27 | Sponsor Protocol Number: TED-C14-006 | Start Date*: 2016-09-19 | |||||||||||
Sponsor Name:NPS Pharmaceuticals, Inc. | |||||||||||||
Full Title: A 24-Week Double-blind, Safety, Efficacy, and Pharmacodynamic Study Investigating Two Doses of Teduglutide in Pediatric Subjects Through 17 Years of Age with Short Bowel Syndrome who are Dependent ... | |||||||||||||
Medical condition: Short Bowel Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) IT (Completed) FI (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000825-35 | Sponsor Protocol Number: U1111-1167-2731 | Start Date*: 2015-08-27 | |||||||||||
Sponsor Name:Rigshospitalet Blegdamsvej | |||||||||||||
Full Title: The effect of the glucagon-like peptide-1 analogue, liraglutide (Victoza®), on jejunostomy output and intestinal absorption in short bowel syndrome patients, a double-blind cross-over study | |||||||||||||
Medical condition: Short bowel syndrome (SBS) is a clinical situation with reduced absorptive mucosal surface due to extensive surgical resection. SBS leads to increased intestinal losses of fluids and electrolytes; ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-002472-16 | Sponsor Protocol Number: CCD09 | Start Date*: 2011-12-19 | |||||||||||
Sponsor Name:Cytonet GmbH & Co KG | |||||||||||||
Full Title: Open, prospective, diagnostic, multicentre study in healthy subjects, patients with urea cycle disorders (UCD), and carriers of UCD mutations, to evaluate in vivo ureagenesis measured after a singl... | |||||||||||||
Medical condition: 1. Healthy subjects 2. Symptomatic UCD patients with genetically confirmed CPSD, OTCD, ASSD, or ASLD 3. Asymptomatic carriers of UCD mutations (e.g. parents) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004797-18 | Sponsor Protocol Number: | Start Date*: 2017-06-26 | |||||||||||
Sponsor Name:Imperial College London | |||||||||||||
Full Title: Pilot study of the GLP-1 agonist, Liraglutide, on decreasing parenteral support requirements in short bowel patients. | |||||||||||||
Medical condition: Intestinal failure with an underlying aetiology of short bowel | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002487-41 | Sponsor Protocol Number: GLY-321-2017 | Start Date*: 2018-01-31 | |||||||||||
Sponsor Name:GLyPharma Therapeutic Inc. (a wholly owned subsidiary of VectivBio Holding AG) | |||||||||||||
Full Title: A Phase Ib/IIa open-label, repeated dose, metabolic balance study of FE 203799 in patients with short bowel syndrome | |||||||||||||
Medical condition: Short bowel syndrome (SBS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-014437-24 | Sponsor Protocol Number: P090203 | Start Date*: 2009-09-23 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: Essai randomisé d'immunonutrition par L-arginine guidée en réanimation non chirurgicale | |||||||||||||
Medical condition: Patients de réanimation non chirurgicale sous ventilation artificielle, non immunodéprimés | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000419-34 | Sponsor Protocol Number: RC15_0475 | Start Date*: 2016-10-24 | |||||||||||
Sponsor Name:CHU de Nantes | |||||||||||||
Full Title: | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-004592-35 | Sponsor Protocol Number: 6836 | Start Date*: 2010-06-16 |
Sponsor Name:Barts Health NHS Trust | ||
Full Title: A Randomised Stratified Multicentre Phase II Clinical Trial of Single-Agent ADI-PEG 20 (Pegylated Arginine Deiminase) in Patients with Malignant Pleural Mesothelioma. | ||
Medical condition: Mesothelioma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-000400-99 | Sponsor Protocol Number: PLMA34 | Start Date*: 2014-09-15 | |||||||||||
Sponsor Name:Radboud university medical center | |||||||||||||
Full Title: 10-day decitabine, fludarabine and 2 Gray TBI as conditioning strategy for poor and very poor risk AML in CR1 | |||||||||||||
Medical condition: Acute myeloid leukemia AML | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-005046-10 | Sponsor Protocol Number: HEMSC42 | Start Date*: 2019-07-23 | ||||||||||||||||
Sponsor Name:Radboud university medical center | ||||||||||||||||||
Full Title: Anakinra: Efficacy of interleukin-1 pathway inhibitor anakinra for the management of fever during neutropenia and mucositis in patients with multiple myeloma receiving an autologous hematopoietic s... | ||||||||||||||||||
Medical condition: Febrile neutropenia and mucositis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-003111-28 | Sponsor Protocol Number: REPO-HFpEF-II | Start Date*: 2023-02-15 | |||||||||||
Sponsor Name:Hospital Clínico Universitario de Valencia | |||||||||||||
Full Title: Mechanism-based drug REpurPOsing in a subtype of Heart Failure with Preserved Ejection Fraction (REPO-HFPEF) | |||||||||||||
Medical condition: Subtype of Heart Failure with Preserved Ejection Fraction | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005129-99 | Sponsor Protocol Number: TA799-013 | Start Date*: 2021-02-10 | |||||||||||
Sponsor Name:VectivBio AG | |||||||||||||
Full Title: A multicenter, open-label, metabolic balance study to evaluate the effects of apraglutide on intestinal absorption in adult subjects with short bowel syndrome, intestinal failure (SBS-IF), and colo... | |||||||||||||
Medical condition: short bowel syndrome, intestinal failure (SBS-IF), colon-in-continuity (CIC) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) BE (Completed) DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-017885-22 | Sponsor Protocol Number: LUD2009-007 | Start Date*: 2012-05-21 | |||||||||||
Sponsor Name:Ludwig Institute for Cancer Research, Ltd | |||||||||||||
Full Title: Phase II Study of ADI-PEG 20 in Patients with Relapsed Sensitive or Refractory Small Cell Lung Cancer | |||||||||||||
Medical condition: Relapsed Sensitive or Refractory Small Cell Lung Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
